Tekla Capital Management LLC Novo Cure LTD Transaction History

Tekla Capital Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$124.11 - $190.17 $10.9 Million - $16.7 Million	-87,918 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$112.16 - $174.14 $3.24 Million - $5.04 Million	-28,927 Reduced 24.76%	87,918 $15.2 Million
Q3 2020 Nov 13, 2020	SELL	$58.05 - $111.31 $858,675 - $1.65 Million	-14,792 Reduced 11.24%	116,845 $13 Million
Q2 2020 Aug 13, 2020	BUY	$57.2 - $74.41 $1.38 Million - $1.8 Million	24,199 Added 22.52%	131,637 $7.81 Million
Q4 2019 Feb 13, 2020	BUY	$68.3 - $93.8 $444,359 - $610,262	6,506 Added 6.45%	107,438 $9.05 Million
Q3 2019 Nov 13, 2019	BUY	$61.86 - $97.8 $2.9 Million - $4.58 Million	46,858 Added 86.66%	100,932 $7.55 Million
Q2 2019 Aug 14, 2019	SELL	$42.22 - $63.23 $501,995 - $751,804	-11,890 Reduced 18.02%	54,074 $3.42 Million
Q1 2019 May 14, 2019	BUY	$31.96 - $56.12 $1.33 Million - $2.33 Million	41,464 Added 169.24%	65,964 $3.18 Million
Q4 2018 Feb 13, 2019	BUY	$28.72 - $52.63 $703,640 - $1.29 Million	24,500 New	24,500 $820,000

262

77M

1.17M

318K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $1.69B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Tekla Capital Management LLC with notifications on news.